HTBX News and Press, Heat Biologics Inc. From 01/27/21

Heat Biologics (HTBX) has fallen ~10.7% in the premarket after the company announced that additional preclinical results of its COVID-19 vaccine candidate were published in Frontiers in Immunology, a peer-reviewed journal.Heat Biologics’ COVID-19 vaccine candid...

T2 Biosystems (TTOO) -20% despite strong Q4 & FY20 prelims.AIkido Pharma (AIKI) -18%.Seanergy Maritime Holdings (SHIP) -18%.Celsion CLSN -15%.Recon Technology (RCON) -15%.TransEnterix (TRXC) -14% after $69.25M capital raise.Ocugen (OCGN) -14%.BIOLASE (BIOL) -15%.P...

Spike specific CD8+ and CD4+ T-cell memory responses observed 30- and 60- days post vaccination DURHAM, NC / ACCESSWIRE / January 27, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to mod...

Heat Biologics (HTBX) is up ~9.0% in the premarket after the company announced that it has engaged CRS Crossroads Strategies, LLC, to assist in advancing government collaborations.With effect from February 01, CRS Crossroads, a bipartisan government relations firm based in...

Heat Biologics, Inc. is a clinical-stage biopharmaceutical stage company focused on developing immune therapies and vaccines. Heat Biologics' pipeline consists of three clinical-stage therapeutics and 1 pre-clinical (COVID-19 vaccine). Heat Biologics' lead therapeutic is HS-110 (viage...

DURHAM, NC / ACCESSWIRE / January 20, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, to...

DURHAM, NC / ACCESSWIRE / January 19, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, ...

DURHAM, NC / ACCESSWIRE / January 11, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, ...

DURHAM, NC / ACCESSWIRE / January 8, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, has...

Zolovax, Inc., a wholly-owned subsidiary of Heat Biologics (HTBX), has entered into an exclusive license agreement with the University of Miami for its UMIP-510 platform. Heat Biologics has also promoted William Ostrander as Chief Financial Officer with effect from January 4, 2021.The ag...